Patrick Lafuma: Merck lately made investors blissful. Right now, Merck is within the lead, reporting constructive part three data from its oral COVID therapy on Friday. And Pfizer will take some market share as effectively if its oral remedy is approved. Merck is a $200 billion company, and Pfizer is a $240 billion pharmaceutical giant. […]